CMRX - キメリックス （Chimerix Inc.） キメリックスCMRXのチャート
CMRXの企業情報
| symbol | CMRx |
|---|---|
| 会社名 | Chimerix Inc. （キメリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 チメリックス（Chimerix Inc.）はバイオ医薬品会社である。同社は未充足の医療ニーズに対処する薬品の発見、開発、商業化を行う。同社のリード化合物brincidofovirは天然痘、アデノウイルス（AdV）、およびヒトヘルペスウイルスを含むデオキシリボ核酸（DNA）ウイルスの治療と予防のための経口および静脈内（IV）製剤として開発中である。同社はノロウイルスの予防、治療ためのCMX521の開発を進める。さらに、同社は治療法の乏しいあるいはないウイルス標的に集中するアクティブな発見プログラムがある。Brincidofovirは人間に感染できる5つのファミリーの二本鎖デオキシリボ核酸（dsDNA）ウイルスすべてに対してスペクトル抗ウイルス活性を示した研究用経口ヌクレオチド類似体である。brincidofovirの経口、IV製剤は活性な抗ウイルスをウイルス複製部位に直接送達する開発階段中である。 キメリックスは、米国のバイオ医薬品会社。経口抗ウイルス薬を発見、開発、商品化する。同社は独自の脂質技術を利用し、2種類のヌクレオチド化合物を開発。「Brincidofovir (CMX001)」は第3相臨床段階にある。「CMX157」は第1相臨床試験を終えた後、メルク・シャ―プ・アンド・ド―ム社へライセンス供与した。 Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The company's three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients. |
| 本社所在地 | 2505 Meridian Parkway Suite 100 Durham NC 27713 USA |
| 代表者氏名 | Martha J. Demski マーサ・J・デムスキー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 919-806-1074 |
| 設立年月日 | 36617 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 82人 |
| url | www.chimerix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cmrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -75.05300 |
| 終値（lastsale） | 3.84 |
| 時価総額（marketcap） | 184420899.84 |
| 時価総額 | 時価総額（百万ドル） 172.89460 |
| 売上高 | 売上高（百万ドル） 4.72400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -1.86840 |
| 当期純利益 | 当期純利益（百万ドル） -74.98900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Chimerix Inc revenues increased 13% to $2M. Net loss increased 12% to $38.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 21% to $25.2M (expense) General and administrative increase of 7% to $8.8M (expense). |
CMRXのテクニカル分析
CMRXのニュース
7 Thrilling Biotech Stocks for Aggressive Investors to Buy 2023/04/05 17:40:01 InvestorPlace
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve’s possible response. If we’re being honest, circumstances don’t look particularly auspicious. Then again, the beauty of biotech stocks to buy is that medical innovations will continue moving forward. Poor economy or not, scientists continue to search for treatments for difficult-to-address diseases and conditions. Under this framework, you might say that the biotech sector is somewhat insulated from the ebb and flow of the economy. For this specific write-up, I’ll be discussing truly thrilling biotech stocks to buy. Each of these securities features (at the time of writing) consensus analyst price targets that imply a minimum of 100% upside potential.
Chimerix says exposure to any SVB liquidity risk is “immaterial” 2023/03/10 15:59:39 Seeking Alpha
Amid funding woes at SVB Financial (SIVB), biotech Chimerix (CMRX), said Friday that its exposure to liquidity concerns at the Silicon Valley Bank is "immaterial." Read the full story here.
Chimerix (CMRX) Investor Presentation - Slideshow 2023/03/07 19:05:19 Seeking Alpha
The following slide deck was published by Chimerix, Inc.
Chimerix: Gaining Traction, Cash Runway To 2027 2023/03/06 14:00:00 Seeking Alpha
Chimerix took quite a skid as it passed into the danger zone. Recognizing that CMRX is at the top of the risk spectrum, see why I still rate it as a strong buy.
The Top 7 Growth Stocks in Biotech 2023/03/03 23:57:06 InvestorPlace
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.
The Top 7 Growth Stocks in Biotech 2023/03/03 23:57:06 InvestorPlace
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics. The rewards for bringing such products to market are significant. But biotech growth stocks also generally carry much higher risk than the average stock. Additionally, companies in the biotech industry face regulatory approval processes and intellectual property disputes that can result in significant near-term volatility. Nevertheless, the potential for substantial returns makes biotech stocks perpetually attractive. Identifying companies with the best chances of developing breakthrough drugs or therapies is paramount to success. Let’s take a look at seven companies that I think fit that profile. ITOS iTeos Therapeutics $17.30 VIR Vir Biotechnology $22.84 BEAM Beam Therapeutics $39.10 KNSA Kiniksa Pharmaceuticals $12.28 DVAX Dynavax Technologies $10.44 CMRX Chimerix $1.63 APVO Aptevo Therapeutics $2.15 iTeos Therapeutics (ITOS) Source: motorolka / Shutterstock.com Stocks like iTeos Therapeutics (NASDAQ: ITOS ) are the kind of equity biotech investors ought to be looking for.
Chimerix, Inc. (CMRX) Q4 2022 Earnings Call Transcript 2023/03/02 15:36:06 Seeking Alpha
Chimerix, Inc. (NASDAQ:NASDAQ:CMRX) Q4 2022 Earnings Conference Call March 2, 2023 8:30 AM ETCompany ParticipantsMichelle LaSpaluto - Vice President-Strategic Planning and Investor…
Chimerix: Q4 Earnings Snapshot 2023/03/02 14:01:33 WTOP
DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Chimerix Inc. (CMRX) on Thursday reported a loss of $21 million in…
Chimerix GAAP EPS of -$0.24 in-line, revenue of $0.8M beats by $0.22M 2023/03/02 12:04:17 Seeking Alpha
Chimerix press release (CMRX): Q4 GAAP EPS of -$0.24 in-line.Revenue of $0.8M (+1500.0% Y/Y) beats by $0.22M.“As we look to 2023, we are making tremendous progress and continuing…
Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update 2023/03/02 12:00:00 GlobeNewswire
- Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study –
Canada signs $32.9M contract for smallpox drug with manufacturer Chimerix - National | Globalnews.ca 2022/06/24 18:00:54 Global News Canada
Chimerix Inc. has been awarded a contract by Canada worth up to $32.9 million for its smallpox drug likely to be used to treat monkeypox as it spreads across the world.
Canada signs $32.9M contract for smallpox drug with manufacturer Chimerix 2022/06/24 18:00:54 Global News Canada
Chimerix Inc. has been awarded a contract by Canada worth up to $32.9 million for its smallpox drug likely to be used to treat monkeypox as it spreads across the world.
Chimerix gets up to $25.3-million contract from Canada for drug likely to be used to treat monkeypox 2022/06/24 15:12:45 The Globe and Mail
The contract, awarded by the Public Health Agency of Canada, comes a day after Chimerix announced an order worth $9.3-million for the smallpox drug, Tembexa
Chimerix ticks higher on new order for smallpox therapy 2022/06/24 15:09:18 Seeking Alpha
The shares of Chimerix (CMRX) rose on Friday after the company announced that Public Health Agency of Canada awarded it a contract to deliver up to $25.3M of Tembexa (brincidofovir),…
Chimerix gets up to $25.3 million contract from Canada for smallpox drug 2022/06/24 14:50:46 Reuters
Chimerix Inc said on Friday it had been awarded a contract worth up to $25.3 million by Canada for its smallpox drug, likely to used to treat monkeypox as the viral infection spreads across the world.